Peptide safety
"Is this safe?" is the right first question. These articles look at peptide safety — what data actually exists for peptides and GLP-1 medications: what trials measured, what has only been studied in animals, how sourcing and compounding affect quality, and which red flags matter when you read claims online.
The prescription requirement exists precisely for this: a licensed provider weighs your health history before anything ships — and can say no. The same standard applies across the site: what a study measured, in whom, and for how long.
227 articles on this topic
-
GHK-Cu Side Effects: Topical vs Injectable
GHK-Cu side effects are usually mild with topical cosmetics, but injectable GHK-Cu has no long-term human safety data. Route is the difference that matters.
-
Tesamorelin Side Effects: Rates, Risks, Monitoring
The most common tesamorelin side effects are injection-site reactions and joint pain; glucose, IGF-1 and cancer history are the monitoring issues that can change the plan.
-
Tirzepatide for Type 2 Diabetes: Trial Results
Across the SURPASS trials, adults assigned to tirzepatide had average HbA1c reductions of roughly 1.9 to 2.4 percentage points over 40 to 52 weeks. The right comparison depends on a person's existing diabetes treatment and clinical risks.
-
Peptide Compounding Pharmacy: What It Does
A peptide compounding pharmacy prepares a prescription for a named patient when no suitable manufactured product meets that patient's need. The meaningful checks are the prescription, the facility's regulatory pathway and its controls for identity, potency and sterility.
-
CJC-1295 No DAC: What the Label Actually Means
CJC-1295 no DAC is label shorthand for modified GRF 1-29, a short-acting GHRH analog without the albumin-binding feature that makes the DAC form last for days.
-
Does Semaglutide Make You Tired? What Trials Show
Yes, fatigue can happen, though it was reported by a minority of people in STEP trials. The timing and accompanying symptoms help distinguish low intake or dehydration from hypoglycemia or another cause.
-
Semaglutide and Alcohol: What to Know
There is no listed direct interaction between semaglutide and alcohol, but the combination can make nausea, dehydration, low blood sugar, and pancreatitis risk more important.
-
What Happens When You Stop Taking Semaglutide
Appetite commonly returns as semaglutide clears, and some weight regain is likely. Trials show why stopping is better treated as a long-term care decision than as a test of willpower.
-
What Is Kisspeptin-10? The Decapeptide Explained
Kisspeptin-10 is the last ten amino acids of the full 54-residue peptide — the shortest fragment that still switches on the receptor. It also clears from human blood in about four minutes, which shapes everything about how it is given.
-
TB-500 Side Effects: What Is Known and What Is Not
Most of what circulates as a TB-500 side effect list is neither reported nor ruled out. The honest version starts with how thin the human safety data is — and with why a seller's clean record is not one.
-
How Long Does Tirzepatide Stay in Your System?
Tirzepatide usually takes about 25–30 days to fall to a small fraction of its starting level after the last dose. Its five-to-six-day half-life explains that estimate, but side effects and clinical effects do not end on one exact day.
-
Ipamorelin Side Effects: What Human Data Shows
Human safety data for ipamorelin are unusually thin. Short-term reports exist, but no published trial tells us how common side effects are with months or years of compounded use.
-
Tirzepatide Diarrhea: How Long It Lasts
Diarrhea is common with tirzepatide, especially after treatment begins or the dose increases. It is usually temporary, but persistent symptoms can cause dehydration and deserve a clinician's attention.
-
Is Tirzepatide Safe? What the Evidence Shows
Safety is not a property of the molecule. It is the dose, the source of the vial, your own medical history, and whether a licensed clinician is accountable for the decision.
-
Is Semaglutide Safe? What the Evidence Shows
Semaglutide has years of trial data and a defined risk profile, but safe is not universal. Eligibility depends on personal history, other medicines, monitoring and exactly what product is dispensed.
-
Tirzepatide and Thyroid Cancer: What We Know
The boxed warning comes from thyroid C-cell tumors in rats, not proof of human cancer. Human studies conflict, so MTC and MEN 2 history remains the decisive screening issue.
-
MOTS-c Side Effects: What Is Known and What Is Not
No completed human trial has measured them. What gets sold as a MOTS-c side-effect profile is assembled from injection-site experience with subcutaneous peptides, from pharmacology, and from what a prescriber screens for.
-
Tirzepatide and Alcohol: The Risks That Matter
There is no alcohol contraindication in the labelling. The real issues are additive nausea, low blood sugar with certain diabetes medicines, a stomach that empties slowly, and pancreatitis risk arriving from two directions.
-
Interstate Medical Licensure Compact Guide
The compact can speed a physician's path to licenses in multiple states, but each license still belongs to one state—and the patient's location still controls the telehealth check.
-
How to Check If a Telehealth Doctor Is Licensed
A license check takes only a few minutes when you use the right source. Start with the clinician's legal name, verify current authority in the state where you will attend the visit, and treat an NPI as a cross-check—not a license.
Page 10 of 12 · 227 articles